Awesome #TumorBoardTuesday this week- excited to see how potential approval (soon?) of enfortumab + pembrolizumab will influence 1L approaches in #metastaticurothelialcarcinoma. Thank you @drfrankiejs & @tompowles1!
---
RT @TumorBoardTues
3/5 #TumorBoardTuesday
🎥 TBT in a video

Tx of #urothelialcarcinoma is changing- some ❓re: adj IO after resection.

🧐 Will ctDNA define pt population for whom adj IO is most likely to ➡️benefit? Ch…
https://twitter.com/TumorBoardTues/status/1641957605764653056

RT @TumorBoardTues
#TumorBoardTuesday
🧬A discussion on shifting mgmt in #UrothelialCarcinoma led by @tompowles1 @drfrankiejs!

➡️Welcome to the FRIDAY NIGHT case wrap up!

🆓 #CME: answer 2 quick ❓
ALL CME 🔗: http://integrityce.com/tbt
CME eval🔗: http://integrityce.com/tbteval

RT @TumorBoardTues
3/5 #TumorBoardTuesday
🎥 TBT in a video

Tx of #urothelialcarcinoma is changing- some ❓re: adj IO after resection.

🧐 Will ctDNA define pt population for whom adj IO is most likely to ➡️benefit? Check out this brief video to walk through tx of localized and metastatic UCC.

RT @TumorBoardTues
4/5 #TumorBoardTuesday

📷 TBT in an image:
Graphic outlines 1L, 2L+ in #metastatic #urothelialcarcinoma.
Next: early use of ADCs (enfortumab-vedotin), ctDNA to better risk stratify; ⬇️ tox by trying to decrease # of chemo cycles.

📚Eudra enrolling: https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-001975-17/ES

RT @TumorBoardTues
#TumorBoardTuesday
🧬A discussion on shifting mgmt in #UrothelialCarcinoma led by @tompowles1 @drfrankiejs!

➡️Welcome to the FRIDAY NIGHT case wrap up!

🆓 #CME: answer 2 quick ❓
ALL CME 🔗: http://integrityce.com/tbt
CME eval🔗: http://integrityce.com/tbteval

RT @TumorBoardTues
3/5 #TumorBoardTuesday
🎥 TBT in a video

Tx of #urothelialcarcinoma is changing- some ❓re: adj IO after resection.

🧐 Will ctDNA define pt population for whom adj IO is most likely to ➡️benefit? Check out this brief video to walk through tx of localized and metastatic UCC.

RT @TumorBoardTues
4/5 #TumorBoardTuesday

📷 TBT in an image:
Graphic outlines 1L, 2L+ in #metastatic #urothelialcarcinoma.
Next: early use of ADCs (enfortumab-vedotin), ctDNA to better risk stratify; ⬇️ tox by trying to decrease # of chemo cycles.

📚Eudra enrolling: https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-001975-17/ES

4/5 #TumorBoardTuesday

📷 TBT in an image:
Graphic outlines 1L, 2L+ in #metastatic #urothelialcarcinoma.
Next: early use of ADCs (enfortumab-vedotin), ctDNA to better risk stratify; ⬇️ tox by trying to decrease # of chemo cycles.

📚Eudra enrolling: https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-001975-17/ES

3/5 #TumorBoardTuesday
🎥 TBT in a video

Tx of #urothelialcarcinoma is changing- some ❓re: adj IO after resection.

🧐 Will ctDNA define pt population for whom adj IO is most likely to ➡️benefit? Check out this brief video to walk through tx of localized and metastatic UCC.

#TumorBoardTuesday
🧬A discussion on shifting mgmt in #UrothelialCarcinoma led by @tompowles1 @drfrankiejs!

➡️Welcome to the FRIDAY NIGHT case wrap up!

🆓 #CME: answer 2 quick ❓
ALL CME 🔗: http://integrityce.com/tbt
CME eval🔗: http://integrityce.com/tbteval

RT @TumorBoardTues
Coming soon: A special FRIDAY edition of the #TumorBoardTuesday wrap up! @tompowles1 @BartsECMC took us through the latest approaches to #urothelialcarcinoma. We'll be covering the highlights and providing a quick visual outline soon!

Coming soon: A special FRIDAY edition of the #TumorBoardTuesday wrap up! @tompowles1 @BartsECMC took us through the latest approaches to #urothelialcarcinoma. We'll be covering the highlights and providing a quick visual outline soon!

RT @JohnEbbenMDPhD
Will be really interesting to see how ADCs + IO may change 1L options in metastatic #urothelialcarcinoma. Wonder whether there are unique tumor-microenvironment effects/synergies with more directed chemo payload delivery into the TME? #TumorBoardTuesday https://twitter.com/tompowles1/status/1640881428861681665

RT @JohnEbbenMDPhD
Good to know when and where to use modalities like PET- not super sensitive in muscle invasive bladder cancer even for distant sites. #urothelialcarcinoma #TumorBoardTuesday https://twitter.com/BartsECMC/status/1640868151142281216

RT @JohnEbbenMDPhD
@BartsECMC @TumorBoardTues @tompowles1 @MPishvaian @adamkibel_uro @DrChoueiri @cdanicas @drenriquegrande @SCUColombia @wroclawski_uro @raymanneh @T_AlonsoGordoa @hannahdzmd @sandysrimd @sumitshahMD What type of ctDNA assays do you like to use here? Is there a Signatera-like/tissue-informed choice in #urothelialcarcinoma, or just a general cell-free DNA approach? #TumorBoardTuesday I imagine this could also be really interesting when treating FGFR fusions w targeted agents.

RT @JohnEbbenMDPhD
Will be really interesting to see how ADCs + IO may change 1L options in metastatic #urothelialcarcinoma. Wonder whether there are unique tumor-microenvironment effects/synergies with more directed chemo payload delivery into the TME? #TumorBoardTuesday https://twitter.com/tompowles1/status/1640881428861681665

Will be really interesting to see how ADCs + IO may change 1L options in metastatic #urothelialcarcinoma. Wonder whether there are unique tumor-microenvironment effects/synergies with more directed chemo payload delivery into the TME? #TumorBoardTuesday
---
RT @tompowles1
@BartsECMC @TumorBoardTues @MPishvaian @JohnEbbenMDPhD @adamkibel_uro @DrChoueiri @cdanicas @drenriquegrande @SCUColombia @wroclawski_uro @raymanneh @T_AlonsoGordoa @h…
https://twitter.com/tompowles1/status/1640881428861681665

RT @JohnEbbenMDPhD
@BartsECMC @TumorBoardTues @tompowles1 @MPishvaian @adamkibel_uro @DrChoueiri @cdanicas @drenriquegrande @SCUColombia @wroclawski_uro @raymanneh @T_AlonsoGordoa @hannahdzmd @sandysrimd @sumitshahMD What type of ctDNA assays do you like to use here? Is there a Signatera-like/tissue-informed choice in #urothelialcarcinoma, or just a general cell-free DNA approach? #TumorBoardTuesday I imagine this could also be really interesting when treating FGFR fusions w targeted agents.

RT @JohnEbbenMDPhD
⏰Starting NOW! Join #TumorBoardTuesday as @drfrankiejs & @tompowles1 as we discuss 1L and neoadjuvant approaches in #UrothelialCarcinoma! @Uromigos @EAU_YAUrotheli @UroDocAsh https://twitter.com/BartsECMC/status/1640866373420085248

RT @JohnEbbenMDPhD
Good to know when and where to use modalities like PET- not super sensitive in muscle invasive bladder cancer even for distant sites. #urothelialcarcinoma #TumorBoardTuesday https://twitter.com/BartsECMC/status/1640868151142281216